Clinical Trial Update: A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial assesses the safety, tolerability, and body-weight effects of pramlintide alone and in combination with oral antiobesity agents in o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• pramlintide (pramlintide)

Snippet

Sponsor: AstraZeneca | Conditions: Overweight, Obesity | Phase 2 | Status: COMPLETED